Share on StockTwits

Equities research analysts at HC Wainwright began coverage on shares of Cytosorbents Corp (NASDAQ:CTSO) in a research note issued to investors on Monday, reports. The firm set a “buy” rating and a $1.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 280.23% from the stock’s previous close.

In other Cytosorbents Corp news, Director Al Kraus sold 100,000 shares of the stock on the open market in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $0.28, for a total value of $28,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Cytosorbents Corp (NASDAQ:CTSO) opened at 0.263 on Monday. Cytosorbents Corp has a 1-year low of $0.09 and a 1-year high of $0.35. The stock’s 50-day moving average is $0.24 and its 200-day moving average is $0.24. The company’s market cap is $78.6 million.

Cytosorbents Corp (NASDAQ:CTSO) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.01) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.01). On average, analysts predict that Cytosorbents Corp will post $-0.04 earnings per share for the current fiscal year.

CytoSorbents Corporation is a development stage critical care focused company using blood purification to treat life-threatening illnesses.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.